Predictors of AAA Expansion and/or Rupture

• Status: Terminated
• Trial end date: 2020-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group).

The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will compare two radiotracers, 18F-FDG and 11C-PBR28 to determine if one provides more useful and reliable information about inflammation. 18F-FDG and 11C-PBR28 are radioactive drugs that will be used for imaging during the PET-CT scan. The investigator will also compare the results describing the mechanical properties of the AAA wall to the degree of inflammation in that wall as determined by PET-CT imaging to define new and better predictors of AAA growth and/or rupture.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion

• All ethnic groups

• 45 years of age or older

• *Must fit into one of the three following groups:

• Control group (atherosclerosis without aneurysmal disease

• Small AAA (3-4.5 cm)

• Rapidly growing AAA (0.5 cm in 6 months or 1 cm in 12 months)

Exclusion

• At risk population (cognitively impaired)

• Any exclusion for PT-CT (i.e., allergy to contrast)

• Any woman planning to become pregnant, suspects pregnancy, pregnant or breastfeeding)

• Any greater than normal potential for cardiac arrest

• Renal disease (eGFR <60 mg/ml/1.73m2)

• Claustrophobic reactions and/or is unable to lie on the exam table for 60 minutes

• Significant radiation exposure via other trials or medical testing